| (Values in U.S. Thousands) | Jun, 2018 | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Neuro-Hitech Inc (NHPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Neuro-Hitech, Inc. is a holding company with assets currently in the Oil and Gas sector and in the pharmaceutical sector. The Company's principal business is operated through two subsidiaries: MCR American Pharmaceuticals (MCR) and AMBI Pharmaceuticals, Inc. (AMBI). The Company was acquired MCR and AMBI. MCR is focused on the acquisition, development, marketing and distribution of cough and cold, prenatal and pain management pharmaceutical products that provide quick and low-cost market entry through the ANDA, and OTC monograph regulatory approval pathways. MCR markets its products primarily to general practice, family practice, internal medicine, pediatric and ear, nose and throat (ENT) physicians. MCR provides physicians with offering of products within the cough, cold, allergy, mild pain management and pre-natal health areas. AMBI is focused on the distribution of generic equivalent pharmaceutical products to pharmaceutical wholesalers, distributors and chain pharmacies.